News
EPRX
7.63
+2.83%
0.21
Eupraxia Pharmaceuticals Reports Open Market Sale Agreement
TipRanks · 3h ago
Eupraxia Pharmaceuticals Establishes US$125 Million At-the-Market Offering Program
TipRanks · 5h ago
Eupraxia Reports Third-Quarter Results, RESOLVE Trial Reaches 120 Patients
TipRanks · 5h ago
Eupraxia Pharmaceuticals Files November 10 Form 6-K With Interim Results
TipRanks · 5h ago
Eupraxia Announces $125M At-The-Market Equity Program; Says No Current Plan To Use ATM Program In Near Term
Benzinga · 5h ago
Eupraxia Pharmaceuticals Q3 EPS $(0.23) Beats $(0.28) Estimate
Benzinga · 5h ago
RBC Capital Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $14
Benzinga · 1d ago
Eupraxia Pharmaceuticals (EPRX) Has a New Rating from RBC Capital
TipRanks · 1d ago
Eupraxia Pharmaceuticals initiated with an Outperform at RBC Capital
TipRanks · 1d ago
Weekly Report: what happened at EPRX last week (1102-1106)?
Weekly Report · 1d ago
Weekly Report: what happened at EPRX last week (1026-1030)?
Weekly Report · 11/02 09:36
Weekly Report: what happened at EPRX last week (1019-1023)?
Weekly Report · 10/26 09:36
Eupraxia Pharmaceuticals: Promising Science, But Competition And Valuation Limit Upside
Seeking Alpha · 10/22 14:23
Eupraxia Pharmaceuticals Launches Conference Roadshow and Analyst Day to Spotlight EP-104GI
TipRanks · 10/22 13:22
Analyst Reiterates Buy on Eupraxia Pharmaceuticals, Sees Attractive Risk-Reward with Unchanged $11 Price Target Ahead of Phase 2b RESOLVE Data
TipRanks · 10/20 20:35
Weekly Report: what happened at EPRX last week (1012-1016)?
Weekly Report · 10/19 09:36
Eupraxia Pharmaceuticals: Buy Rating Reaffirmed on Strong Phase 2b Setup and Favorable Risk-Reward After Price Target Cut to $11
TipRanks · 10/15 16:55
Eupraxia Pharmaceuticals Hits RESOLVE Trial Enrollment Target Ahead of December Interim Data
TipRanks · 10/15 14:28
Eupraxia Pharmaceuticals reaches enrollment target for RESOLVE study
TipRanks · 10/15 12:11
Eupraxia Reaches Its Target Enrollment Of 120 Patients In Phase 2b Placebo-Controlled Blinded Portion Of RESOLVE Trial
Benzinga · 10/15 12:03
More
Webull provides a variety of real-time EPRX stock news. You can receive the latest news about Eupraxia Pharmac through multiple platforms. This information may help you make smarter investment decisions.
About EPRX
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.